Valemetostat
Valemetostat is a novel antineoplastic agent that is currently under investigation for its potential use in the treatment of various types of cancer. It is classified as a dual inhibitor of the EZH1 and EZH2 enzymes, which are part of the polycomb repressive complex 2 (PRC2). These enzymes play a crucial role in the regulation of gene expression through histone methylation.
Mechanism of Action[edit | edit source]
Valemetostat functions by inhibiting the activity of both EZH1 and EZH2, which are involved in the trimethylation of histone H3 at lysine 27 (H3K27me3). This modification is associated with the repression of tumor suppressor genes and the promotion of oncogenesis. By inhibiting these enzymes, valemetostat can potentially restore the expression of tumor suppressor genes and inhibit the growth of cancer cells.
Clinical Development[edit | edit source]
Valemetostat is currently being evaluated in various clinical trials for its efficacy and safety in treating different types of cancer, including lymphomas and solid tumors. Early-phase clinical trials have shown promising results, with some patients experiencing significant tumor reduction.
Potential Indications[edit | edit source]
Valemetostat is being investigated for use in several types of cancer, including:
Side Effects[edit | edit source]
As with many antineoplastic agents, valemetostat may cause a range of side effects. Commonly reported side effects include:
Research and Future Directions[edit | edit source]
Ongoing research aims to further elucidate the full therapeutic potential of valemetostat, including its efficacy in combination with other anticancer agents. Future studies will also focus on identifying biomarkers that can predict response to treatment and on optimizing dosing regimens to minimize side effects.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
